1
|
Ramos-Ruperto L, Arcos-Rueda MDM, de Miguel-Buckley R, Busca-Arenzana C, Mican R, Montejano R, Delgado-Hierro A, Montes ML, Valencia ME, Serrano L, Arribas JR, González J, Bernardino JI, Martín-Carbonero L. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV. HIV Med 2024; 25:684-691. [PMID: 38379338 DOI: 10.1111/hiv.13617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Accepted: 01/12/2024] [Indexed: 02/22/2024]
Abstract
INTRODUCTION Dolutegravir + rilpivirine (DTG + RPV) is an effective antiretroviral therapy regimen approved in clinical guidelines as a switch therapy for virologically suppressed people with HIV. Our study aimed to compare the effectiveness and tolerability of DTG + RPV in women and men in real-world clinical practice. METHODS This was a retrospective analysis of treatment-experienced people with HIV from a large HIV unit who switched to DTG + RPV. We analysed treatment effectiveness, rates of adverse events and discontinuation, and metabolic changes after 48 weeks of treatment. HIV-RNA levels <50 copies/mL were analysed at 48 weeks using both intention-to treat analysis (where missing data were interpreted as failures) and per-protocol analysis (excluding those with missing data or changes due to reasons other than virological failure). Outcomes were compared between women and men based on sex at birth. RESULTS A total of 307 patients were selected (71 women and 236 men). No transgender people were included. At baseline, women had lived with HIV infection and received antiretroviral therapy for longer than men (23.2 vs 17.4 years and 18.9 vs 14.2 years, respectively). In the intention-to-treat analysis, 74.6% (95% confidence interval [CI] 63.4-83.3%) of women and 83.5% (95% CI 78.2-87.7) of men had HIV-RNA <50 copies/mL. In the per-protocol analysis, 96.4% (95% CI 87.7-99) of women and 99% (95% CI 98.9-99.7) of men had HIV-RNA levels <50 copies/mL. Two women and two men had HIV-RNA >50 copies/mL at 48 weeks. Discontinuation due to adverse events was more frequent in women than in men: 12.7% vs 7.2% (p < 0.02). Neuropsychiatric and gastrointestinal events were the most frequently reported. A median (interquartile range) weight gain of 1.9 kg (0-4.2) in women and 1.2 kg (-1-3.1) in men was reported (median of differences between baseline visit and week 48); the remaining changes in metabolic parameters were neutral. CONCLUSIONS DTG + RPV exhibited good and similar virological effectiveness in women and men in real-world settings. However, poorer tolerability and more treatment interruptions were observed in women.
Collapse
Affiliation(s)
- Luis Ramos-Ruperto
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
| | - Maria Del Mar Arcos-Rueda
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
| | - Rosa de Miguel-Buckley
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| | - Carmen Busca-Arenzana
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| | - Rafael Mican
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| | - Rocío Montejano
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| | - Ana Delgado-Hierro
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
| | - María Luisa Montes
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| | - María Eulalia Valencia
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
| | - Lucía Serrano
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
| | - José Ramon Arribas
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| | - Juan González
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| | - Jose Ignacio Bernardino
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| | - Luz Martín-Carbonero
- HIV Unit, Internal Medicine Department, La Paz-Carlos III University Hospital, IdiPaz, Madrid, Spain
- CIBER de Enfermedades Infecciosas CIBER INFECC, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
2
|
Suárez-García I, Gutierrez F, Pérez-Molina JA, Moreno S, Aldamiz T, Valencia Ortega E, Curran A, Gutiérrez González S, Asensi V, Amador Prous C, Jarrin I, Rava M. Mortality due to non-AIDS-defining cancers among people living with HIV in Spain over 18 years of follow-up. J Cancer Res Clin Oncol 2023; 149:18161-18171. [PMID: 38008809 PMCID: PMC10725373 DOI: 10.1007/s00432-023-05500-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 10/30/2023] [Indexed: 11/28/2023]
Abstract
PURPOSE Our aim was to describe non-AIDS-defining cancer (NADC) mortality among people living with HIV (PLWH), to compare it with that of the general population, and to assess potential risk factors. METHODS We included antiretroviral-naive PLWH from the multicentre CoRIS cohort (2004-2021). We estimated mortality rates and standardised mortality ratios (SMRs). We used cause-specific Cox models to identify risk factors. RESULTS Among 17,978 PLWH, NADC caused 21% of all deaths observed during the follow-up. Mortality rate due to NADC was 1.58 (95%CI 1.36, 1.83) × 1000 person-years and lung and liver were the most frequent cancer-related causes of death. PLWH had 79% excess NADC mortality risk compared to the general population with the highest SMR found for Hodgkin lymphoma, anal and liver cancers. The SMRs decreased with age and were the highest in age groups under 50 years. The most important prognostic factor was low CD4 count, followed by smoking, viral hepatitis and HIV transmission through heterosexual contact or injection drug use. CONCLUSION Non-AIDS cancers are an important cause of death among PLWH. The excess mortality related to certain malignancies and the association with immunodeficiency, smoking, and coinfections highlights the need for early detection and treatment of cancer in this population.
Collapse
Affiliation(s)
- I Suárez-García
- Grupo de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Infanta Sofía, FIIB HUIS HHEN, Madrid, Spain
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - Félix Gutierrez
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Hospital General Universitario de Elche and Universidad Miguel Hernández, Alicante, Spain
| | - José A Pérez-Molina
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| | - Santiago Moreno
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
| | - Teresa Aldamiz
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Hospital Gregorio Marañón Servicio de Enfermedades Infecciosas/Microbiología Clínica Instituto de Investigación Gregorio Marañón, Madrid, Spain
| | | | - Adrián Curran
- Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Sara Gutiérrez González
- Servicio de Medicina Interna, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Víctor Asensi
- Infectious Diseases Unit, Hospital Universitario Central de Asturias and Group of Translational Research in Infectious Diseases, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | | | - Inma Jarrin
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
| | - Marta Rava
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
- Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
3
|
Toyos S, Berrocal L, González-Cordón A, Inciarte A, de la Mora L, Martínez-Rebollar M, Laguno M, Fernández E, Ambrosioni J, Chivite I, de Lazzari E, Blanco JL, Martínez E, Miró JM, Mallolas J, Torres B. Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020. Euro Surveill 2023; 28:2200317. [PMID: 36892474 PMCID: PMC9999459 DOI: 10.2807/1560-7917.es.2023.28.10.2200317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 11/22/2022] [Indexed: 03/10/2023] Open
Abstract
BackgroundEpidemiological and immunovirological features of people living with HIV (PLWH) can vary by sex.AimTo investigate, particularly according to sex, characteristics of PLWH who consulted a tertiary hospital in Barcelona, Spain, in 1982-2020.MethodsPLWH, still in active follow-up in 2020 were retrospectively analysed by sex, age at diagnosis, age at data extraction (December 2020), birth place, CD4+ cell counts, and virological failure.ResultsIn total, 5,377 PLWH (comprising 828 women; 15%) were included. HIV diagnoses in women appeared to decrease from the 1990s, representing 7.4% (61/828) of new diagnoses in 2015-2020. From 1997, proportions of new HIV diagnoses from patients born in Latin America seemed to increase; moreover, for women born outside of Spain, the median age at diagnosis appeared to become younger than for those born in Spain, with significant differences observed in 2005-2009 and 2010-2014 (31 vs 39 years (p = 0.001), and 32 vs 42 years (p < 0.001) respectively), but not in 2015-2020 (35 vs 42 years; p = 0.254). Among women, proportions of late diagnoses (CD4+ cells/mm3 < 350) were higher than men (significantly in 2015-2020: 62% (32/52) vs 46% (300/656); p = 0.030). Initially, virological failure rates were higher in women than men, but they were similar in 2015-2020 (12% (6/52) vs 8% (55/659); p = 0.431). Women ≥ 50 years old represented 68% (564/828) of women actively followed up in 2020.ConclusionsWomen still have higher rates of late HIV diagnoses than men. Among currently-followed-up women, ≥ 50 year-olds, who need age-adapted care represent a high percentage. Stratifying PLWH by sex matters for HIV prevention and control interventions.
Collapse
Affiliation(s)
- Sara Toyos
- Hospital Verge de la Cinta, Tortosa, University of Barcelona, Barcelona, Spain
| | - Leire Berrocal
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Ana González-Cordón
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Alexy Inciarte
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Lorena de la Mora
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - María Martínez-Rebollar
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Montserrat Laguno
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| | - Emma Fernández
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Juan Ambrosioni
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| | - Iván Chivite
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Elisa de Lazzari
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - José Luis Blanco
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| | - Esteban Martínez
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| | - José M Miró
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| | - Josep Mallolas
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| | - Berta Torres
- HIV Unit, Infectious Diseases Service, Hospital Clínic, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| |
Collapse
|